Lipopolysaccharide-binding protein as a risk factor for development of infectious and inflammatory postsurgical complications in colorectal cancer patients

被引:1
|
作者
Turgunov, Yermek [1 ]
Ogizbayeva, Alina [1 ]
Akhmaltdinova, Lyudmila [2 ]
Shakeyev, Kayrat [1 ]
机构
[1] NJSC Karaganda Med Univ, Dept Surg Dis, 40 Gogol Str, Karaganda, Kazakhstan
[2] NJSC Karaganda Med Univ, Collect Use Lab Res Ctr, Karaganda, Kazakhstan
来源
关键词
lipopolysaccharide-binding protein; colorectal cancer; bowel ob-struction; bacterial translocation; SIRS; complications; SEVERE SEPSIS; LPS; TRANSLOCATION; CD14; LBP; BACTERIA; SERUM; GUT;
D O I
10.5114/wo.2021.110051
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Aim of the study: In this pilot study lipopolysaccharide-binding protein (LBP) levels were assessed as a pos-sible risk factor for development of systemic inflammatory response syndrome (SIRS) and infectious and inflammatory complications in colorectal cancer (CRC) patients after surgery. Material and methods: For LBP determination venous blood was taken 1 hour before the surgery and 72 hours after it. All patients were stratified by the presence or absence of acute bowel obstruction (ABO), SIRS and complications. Results: 36 patients with CRC participated in the study. The LBP level before surgery was 879.8 +/- 221.8 ng/ml (interquartile range (IQR) 749.3- 1028.8); on the 3rd day it was 766.5 +/- 159.4 ng/ml (IQR 669.5-847.6), which was a statistically significant decrease (p = 0.004). A decrease in LBP level by more than 280 ng/ml increases the probability of SIRS and complications in operated CRC patients (OR 6.6, 95% CI: 1.1-40.9 and OR 12.0, 95% CI: 1.8-80.4, respectively). In patients with ABO in the presence of SIRS, the LBP value decreased more than in those without SIRS (p = 0.046). Conclusions: This study demonstrated that the LBP level in the operated CRC patients tends to decrease on the 3rd day after surgery. A bigger decrease in LBP level increases the probability of SIRS and postoperative infectious and inflammatory complications. Therefore, further studies with larger numbers of patients are required.
引用
收藏
页码:198 / 203
页数:6
相关论文
共 50 条
  • [1] The dynamics of the lipopolysaccharide-binding protein (LBP) level in assessing the risk of adverse outcomes in operated colorectal cancer patients
    Turgunov, Yermek
    Ogizbayeva, Alina
    Shakeyev, Kayrat
    Mugazov, Miras
    Akhmaltdinova, Lyudmila
    Nuraly, Shynggys
    Rudolf, Viktor
    [J]. ASIAN JOURNAL OF SURGERY, 2024, 47 (08) : 3435 - 3441
  • [2] Lipopolysaccharide-Binding Protein: A New Biomarker for Infectious Endocarditis?
    Vollmer, Tanja
    Piper, Cornelia
    Kleesiek, Knut
    Dreier, Jens
    [J]. CLINICAL CHEMISTRY, 2009, 55 (02) : 295 - 304
  • [3] Serum lipopolysaccharide-binding protein in endotoxemic patients with inflammatory bowel disease
    Pastor Rojo, Oscar
    Lopez San Roman, Antonio
    Albeniz Arbizu, Eduardo
    de la Hera Martinez, Antonio
    Ripoll Sevillano, Eduardo
    Albillos Martinez, Agustin
    [J]. INFLAMMATORY BOWEL DISEASES, 2007, 13 (03) : 269 - 277
  • [4] Plasma lipopolysaccharide-binding protein and colorectal cancer risk: a nested case–control study in the Multiethnic Cohort
    Jessica S. Citronberg
    Lynne R. Wilkens
    Loic Le Marchand
    Unhee Lim
    Kristine R. Monroe
    Meredith A. J. Hullar
    Emily White
    Polly A. Newcomb
    Johanna W. Lampe
    [J]. Cancer Causes & Control, 2018, 29 : 115 - 123
  • [5] Presepsin (soluble CD14 subtype) as a risk factor for the development of infectious and inflammatory complications in operated colorectal cancer patients
    Shakeyev, Kayrat
    Turgunov, Yermek
    Ogizbayeva, Alina
    Avdiyenko, Olga
    Mugazov, Miras
    Grigolashvili, Sofiko
    Azizov, Ilya
    [J]. ANNALS OF COLOPROCTOLOGY, 2022, 38 (06) : 442 - 448
  • [6] Plasma lipopolysaccharide-binding protein and colorectal cancer risk: a nested case-control study in the Multiethnic Cohort
    Citronberg, Jessica S.
    Wilkens, Lynne R.
    Le Marchand, Loic
    Lim, Unhee
    Monroe, Kristine R.
    Hullar, Meredith A. J.
    White, Emily
    Newcomb, Polly A.
    Lampe, Johanna W.
    [J]. CANCER CAUSES & CONTROL, 2018, 29 (01) : 115 - 123
  • [7] Plasma lipopolysaccharide-binding protein and colorectal cancer risk: A nested case -control study in the Multiethnic Cohort (MEC)
    Citronberg, Jessica
    Wilkens, Lynne
    Le Marchand, Loic
    Lim, Unhee
    Huller, Meredith
    White, Emily
    Newcomb, Polly
    Lampe, Johanna
    [J]. CANCER RESEARCH, 2016, 76
  • [8] The level of lipopolysaccharide-binding protein is significantly increased in plasma in patients with the systemic inflammatory response syndrome
    Myc, A
    Buck, J
    Gonin, J
    Reynolds, B
    Hammerling, U
    Emanuel, D
    [J]. CLINICAL AND DIAGNOSTIC LABORATORY IMMUNOLOGY, 1997, 4 (02) : 113 - 116
  • [9] Bacterial Lipopolysaccharide, Lipopolysaccharide-Binding Protein, and Other Inflammatory Markers in Obesity and After Bariatric Surgery
    Tuomi, Kathryn
    Logomarsino, John V.
    [J]. METABOLIC SYNDROME AND RELATED DISORDERS, 2016, 14 (06) : 279 - 288
  • [10] Lipopolysaccharide-binding protein is efficient in biodosimetry during radiotherapy of lung cancer
    Chalubinska-Fendler, Justyna
    Fendler, Wojciech
    Spych, Michal
    Wyka, Krystyna
    Luniewska-Bury, Jolanta
    Fijuth, Jacek
    [J]. BIOMEDICAL REPORTS, 2016, 5 (04) : 450 - 454